FindTrial
Sign In

Clinical and immunological profile of systemic lupus erythematosis with evaluation of disease activity.

Clinical and immunological profile of systemic lupus erythematosus with special emphasis on neutrophil lymphocyte ratio and mean platelet volume as markers of disease activity.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034122
Enrollment
123
Registered
2021-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M32- Systemic lupus erythematosus (SLE)

Interventions

None listed

Sponsors

DR Manjunath Hande
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients >18-year-old diagnosed as SLE with new ACR and EULAR criteria/ SLICC criteria

Exclusion criteria

Exclusion criteria: Patient with sepsis/other active infections Overlap syndromes with other rheumatological diseases Acute/chronic kidney disease (other than lupus nephritis) Leukaemia, lymphoma, malignancies Vasculitis Acute MI, Acute stroke Patients on systemic steroids >5mg/day Uncontrolled diabetes HbA1c > 7%

Design outcomes

Primary

MeasureTime frame
To have good study about the clinical characteristics of patients of SLE presenting to the hospital To know the immunological profile of patients of SLE Timepoint: At baseline—

Secondary

MeasureTime frame
significant increase in neutrophil lymphocyte ratio in people with active SLE significant reduction in mean platelet volume in patients with active SLE active SLE based on SLEDAI score Timepoint: At baseline—

Countries

India

Contacts

Public ContactSatinder pal singla

Kasturba Medical College Manipal

manjunath.hande@manipal.edu

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026